BMEA
What one share of Biomea Fusion holds
Pharmaceutical Preparations
We are a clinical‑stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases.
Biomea Fusion’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.47 |
|---|---|
| Cash and investments | $0.48 |
| Book value | $0.17 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$0.20 | — | −$0.21 | — | −$0.00 |
| 2020 | — | −$0.51 | $0.00 | −$0.43 | — | $0.43 |
| 2021 | — | −$1.74 | $0.13 | −$1.62 | — | $6.14 |
| 2022 | — | −$2.80 | $0.04 | −$2.17 | — | $3.67 |
| 2023 | — | −$3.44 | $0.10 | −$2.93 | — | $4.72 |
| 2024 | — | −$3.83 | $0.01 | −$3.33 | — | $1.42 |
| 2025 | — | −$1.18 | — | −$1.35 | — | $0.41 |